Boehringer and AbbVie settle biosimilar patent dispute

14 May 2019

Boehringer Ingelheim today announced the resolution of all intellectual property-related litigation with US major AbbVie (NYSE: ABBV) concerning the German drugmaker’s biosimilar Cyltezo (adalimumab-adbm) and the reference medicine Humira(adalimumab), marking yet another patent settlement by AbbVie over its mega blockbuster drug.

AbbVie’s share price was up 1.83% at $78.28 by late morning trading.

“We are proud of the role we play in raising public awareness of biosimilars and being able to stimulate competition to bring more affordable treatment options to US patients,” said Sheila Denton, senior vice president and US general counsel, Legal & Government Affairs/Public Policy, at family-owned Boehringer Ingelheim. “This resolution provides clarity regarding the availability of Cyltezo and allows us to focus on serving patients who need to manage their chronic disease,” she noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK